Infectious Diseases Unit, Alfred Hospital, Melbourne, Victoria, Australia.
PLoS One. 2013;8(2):e56047. doi: 10.1371/journal.pone.0056047. Epub 2013 Feb 12.
A large proportion of patients receiving antiretroviral therapy (ART) in low and middle income countries (LMICs) have unknown treatment outcomes and are classified as lost to follow-up (LTFU). Physical tracing of patients classified as LTFU is common; however, effects of tracing on outcomes remains unclear. The objective of this systematic review is to compare estimates of LTFU, mortality and retention in LMIC in cohorts of patients with and without physical tracing.
We systematically identified studies in LMIC programmatic settings using MEDLINE (2003-2011) and HIV conference abstracts (2009-2011). Studies reporting the proportion LTFU 12-months after ART initiation were included. Tracing activities were determined from manuscripts or by contacting study authors. Studies were classified as "tracing studies" if physical tracing was available for the majority of patients. Summary estimates from the 2 groups of studies (tracing and non-tracing) for LTFU, mortality, stop of ART, transfers out, and retention on ART were determined. 261 papers and 616 abstracts were identified of which 39 studies comprising 54 separate cohorts (n = 187,666) met inclusion criteria. Of those, physical tracing was available for 46% of cohorts. Treatment programs with physical tracing activities had lower estimated LTFU (7.6% vs. 15.1%; p<.001), higher estimated mortality (10.5% vs. 6.6%; p = .006), higher retention on ART (80.0 vs. 75.8%; p = .04) and higher retention at the original site (80.0% vs. 72.9%; p = .02).
Knowledge of patient tracing is critical when interpreting program outcomes of LTFU, mortality and retention. The reduction of the proportion LTFU in tracing studies was only partially explained by re-classification of unknown outcomes. These data suggest that tracing may lead to increased re-engagement of patients in care, rather than just improved classification of unknown outcomes.
在中低收入国家(LMICs),很大一部分接受抗逆转录病毒治疗(ART)的患者其治疗结局未知,被归类为失访(LTFU)。对被归类为 LTFU 的患者进行身体追踪是很常见的;然而,追踪对结局的影响尚不清楚。本系统评价的目的是比较有和没有身体追踪的患者队列中 LTFU、死亡率和保留率的估计值。
我们使用 MEDLINE(2003-2011 年)和 HIV 会议摘要(2009-2011 年)系统地在 LMIC 规划环境中识别研究。纳入报告 ART 启动后 12 个月 LTFU 比例的研究。通过手稿或联系研究作者确定追踪活动。如果大多数患者都可以进行身体追踪,则将研究归类为“追踪研究”。从 2 组研究(追踪和非追踪)中确定 LTFU、死亡率、ART 停止、转出和 ART 保留的汇总估计值。共确定了 261 篇论文和 616 篇摘要,其中 39 项研究(n=187666)包含 54 个独立队列符合纳入标准。其中,46%的队列可以进行身体追踪。有身体追踪活动的治疗项目估计 LTFU 较低(7.6%比 15.1%;p<.001),死亡率较高(10.5%比 6.6%;p=0.006),ART 保留率较高(80.0%比 75.8%;p=0.04),原地点保留率较高(80.0%比 72.9%;p=0.02)。
在解释 LTFU、死亡率和保留率的项目结果时,了解患者追踪情况至关重要。在追踪研究中,LTFU 比例的降低仅部分归因于未知结局的重新分类。这些数据表明,追踪可能导致患者重新参与护理,而不仅仅是改善未知结局的分类。